Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
First immunogenicity data now expected in mid-2019 CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), […]